AI-driven bioinformatics company Tempus has partnered with UK pharma giant AstraZeneca to conduct a trial on non-small cell lung cancer (NSCLC) aimed at creating a comprehensive dataset for biomarker discovery and precision medicine development.
The partnership involves enrolling two cohorts of NSCLC patients in the GEMINI trial. Tempus will utilize its sequencing assays to analyze the molecular profile of patients with stage IV NSCLC and early-stage disease eligible for surgery. The study will track patients for up to three years to understand tumor biology changes during disease progression and treatment.
The findings could lead to the identification of new biomarkers, including circulating tumor DNA for measuring minimal residual disease (MRD). Tempus will leverage its multimodal data library and clinical trial matching program to enhance the study's reach and representativeness across the US patient population.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.